Curcumin therapy: Immune booster in present and post-pandemic (COVID-19) Era
Article Sidebar
-
COVID-19, Curcumin, Cytokine, NF-қB, SARS-COV2
Abstract
COVID-19 pandemic, which has traumatized the world population, in principle, is an inflammatory lung disease secondary to SARS-COV2 virus infection. Inflammatory lung injury progressing to Acute Respiratory Distress Syndrome (ARDS) is a recognized clinical feature of the disease. Inflammatory cytokines released in response to COVID-19 activate the transcription factor - the nuclear factor-қB (NF-қB) and series of pro-inflammatory cytokines, which are responsible for lung injury. Accurate yet precise treatment of coronavirus disease still remains inconclusive, and intervention is mainly symptomatic treatment, respiratory support, antiviral therapies and vaccination. Currently, the major focus of therapy is on reducing lung inflammation by elevating the host immunity. In this scenario, NF-қB inhibition can be conceptualized as a promising approach to down-regulate the overproduction of cytokines, such that inflammatory lung tissue injury could be prevented in COVID-19 infected patients. Towards this, curcumin from Curcuma longa (Turmeric) would play a vital role in the intervention and suppress NF-қB activation via translocation of p65 into the nucleus. Moreover, Curcumin is a proven therapeutic agent against various inflammatory pathologies as it also has the potential to inhibit the expression of certain genes that are critical for the regulation of inflammation. Keeping this phenomenon and the current medical significance in view, we have explored and computed the anti-inflammatory properties of curcumin to develop it as a potent therapeutic agent to prevent NF-қB induced lung tissue injury in COVID-19 with the main goal of elevating immunity in the post-covid-19 situations as well as in healthy human beings.
Full text article
References
Aggarwal, S., Ichikawa, H., Takada, Y., Sandur, S. K., Shishodia, S., Aggarwal, B. B. 2006. Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt Activation. Molecular Pharmacology, 69(1):195–206.
Albert, S., Baldwin, J. 2001. Series Introduction: The transcription factor NF-κB and human disease. Journal of Clinical Investigation, 107(1):3–6.
Attaway, A. H., Scheraga, R. G., Bhimraj, A., Biehl, M., Hatipoglu, U. 2021. Severe Covid-19 pneumonia: Pathogenesis and clinical management. British Medical Journal, 372(2):14–21.
Avasarala, S., Zhang, F., Liu, G., Wang, R., London, S. D., London, L. 2013. Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome. PLOS One, 8(2):280–285.
Bisht, S., et al. 2007. Polymeric nanoparticle-encapsulated curcumin (”nano curcumin”): a novel strategy for human cancer therapy. Journal of Nanobiotechnology, 5(3):1–18.
Conti, P., et al. 2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. Journal of Biological Regulators and Homeostatic Agents, 34(2):327–331.
Cruz, A. S., et al. 2021. Interleukin-6 is a biomarker for the development of fatal Severe Acute Respiratory Syndrome coronavirus 2 Pneumonia. Frontiers in immunology, 12:613422.
Dauphas, S. 2005. The supramolecular organisation of beta-casein: effect on interfacial properties. Food Hydrocolloids, 19(3):387–393.
De Girolamo, L., Peretti, G. M., Maffuli, N., Brini, A. T. 2020. COVID-19, the real role of NSAIDS in Italy. Journal of Orthopaedic Surgery and Research, 15(1):163–165.
Edward, L. R., et al. 2017. The anti-inflammatory activity of curcumin is mediated by its oxidative metabolites. Journal of Biological Chemistry, 292(52):21243–21252.
Gattinoni, L., Coppola, S., Cressoni, M., Busana, M., Rossi, S., Chiumello, D. 2020. Covid 19 does not lead to a “Typical” Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 201(10):1299–1300.
Hariharan, A., Hakeem, A. R., Radhakrishnan, S., Reddy, M. S., Rela, M. 2021. The role and therapeutic potential of NF-Kappa-B pathway in severe COVID-19 patients. Inflammopharmacology, 29(1):91–100.
Huscher, D., et al. 2009. Dose-related patterns of glucocroticoid-induced side effects. Annals of the Rheumatic Diseases, 68(7):1119–1124.
Jeon, Y. J., et al. 2000. Dexamethasone inhibits IL- 1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation. Immunopharmacology, 48(2):173–183.
Jeyanathan, M., Afkami, S., Smaill, F., Miller, M. S., Lichty, B. D., Xing, Z. 2020. Immunological considerations for COVID-19 vaccine strategies. Nature Reviews, Immunology, 20(10):615–632.
Kim, D. C., Ku, S. K., Bae, J. S. 2012. Anticoagulant activity of curcumin and its derivative. BMB reports, 45(4):221–226.
Langeresis, J. D., Raijmakers, H. A., Ulfman, L. H., Koenderman, L. 2010. Abrogation of NF-κB signaling in human neutrophils induce neutrophil survival through sustained p-38 MAPK activation. Journal of Leukocyte Biology, 88(4):655–664.
Langeresis, J. D., Raijmakers, H. A., Ulfman, L. H., Koenderman, L., Das, L., Vinayak, M. 2014. Curcumin attenuates carcinogenesis by downregulating proinflammatory cytokine interleukin-1 (IL-1α and IL-1β) via modulation of AP-1 and NF-IL6 in lymphoma bearing mice. International Immunopharmacology, 20(1):141–147.
Lelli, D., Sahebkar, A., Jhonson, T. P., Pedone, C. 2017. Curcumin uses in pulmonary diseases: state of the art and future perspectives. Pharmacology Research, 115(2):133–148.
Lu, R., et al. 2020. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 395(10224):565–574.
Rattis, B. A., Ramos, S. G., Celes, R. N. 2021. Curcumin as a potential treatment for Covid 19. Frontiers of Pharmacology, 12:1–14.
Sarada, S. K. S., Titto, M., Himadri, P., Saumya, S., Vijayalakshmi, V. 2015. Curcumin prophylaxis mitigates the incidence of hypobaric hypoxia-induced altered ion channel expression and impaired tight junction protein integrity in the rat brain. Journal of Neuroinflammation, 12:97–113.
Sirsidthi, K., Kosai, P., Jiraungkoorskul, K., Jiraungkoorskul, W. 2016. Antithrombotic activity of turmeric (Curcuma longa): A review. Indian Journal of agricultural research, 50(2):101–106.
Vranken, B., Dellicour, S., Smith, D. M., Chaillon, A. 2021. Phylogenic analyses of SARS CoV 2B.1.1.7 lineage suggest a single origin followed by multiple exportation events versus convergent evolution. Clinical Infectious Diseases.
Wan, Y., Shang, J., Graham, R., Baric, R. S., Li, F. 2020. Receptor recognition by a novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. Journal of Virology, 94(7):127–130.
Wang, D., et al. 2020. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Journal of American Medical Association, 323(11):1061–1069.
Yu, H. L., Huang, Q. R. 2010. Enhanced in vitro anti-cancer activity of curcumin encapsulated in hydrophobically modified starch. Food Chemistry, 119(2):669–674.
Zhu, R. F., et al. 2008. Protective effect of curcumin on oleic-induced acute lung injury in rats. China Journal of Chinese material medica, 33(17):2141–2145.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.